Background: Amyloid β (Aβ) peptides are the products of the catalytic processing of the Aβ precursor protein (APP) by the β-secretase, BACE1 and the γ-secretase complex. Impairment of the Aβ production/clearance balance is the major pathophysiological hypothesis in Alzheimer's disease (AD). Plasma Aβ levels are easy to measure in large numbers and therefore can be used as an endophenotype to study the genetics of Aβ and its relevance to AD.
Introduction
Amyloid β (Aβ) peptides are the products of the catalytic processing of the Aβ precursor protein (APP) by the β-secretase, BACE1 and the γ-secretase complex. 1 Aβ peptides are mainly produced in the brain where APP and BACE1 are both highly expressed, 1 but also in circulating blood platelets 2 and in the pancreas. 1 Aβ peptides are able to self-assemble in soluble Aβ oligomers but also in insoluble fibrils that can aggregate as plaques in the brain parenchyma or in the wall of pial blood vessels where they constitute defining hallmarks of Alzheimer's disease (AD) 3 and cerebral amyloid angiopathy (CAA), 4 respectively.
There is strong evidence pointing toward a central role of Aβ peptides in the pathophysiology of AD, although the exact role remains controversial. 5 Studies have shown that a large variety of individually rare mutations in genes involved in Aβ production, including APP, PSEN1 and PSEN2, lead to autosomal dominant early-onset forms of AD (EOAD) and to lobar hemorrhage from cerebral amyloid angiopathy. 6 Moreover, Apolipoprotein E (APOE) ε4, the major genetic risk factor for late-onset AD (LOAD) in the general population, 7 has been implicated in Aβ aggregation, deposition and clearance, both in brain and in blood vessels. 8 These findings are the basis of drug discovery efforts targeting Aβ production and clearance that are currently under consideration in clinical trials, although unfortunately with negative results up to now. 9 Although these results appear to contradict the amyloid hypothesis, several explanations have been advanced. 10 One major concern is the ineffectiveness of intervention after the onset of clinical symptoms which likely result from irreversible neurodegeneration. Since the amyloid accumulation process precedes the clinical onset by decades, 11, 12 early intervention in high risk groups such as Down syndrome patients and APOEε4/ε4 carriers remains to be evaluated. Another concern is the lack of knowledge concerning the precise mechanisms involving Aβ in the pathophysiology of LOAD. Indeed, except for APOE and SORL1, only a small number of genes identified by genome-wide association studies (GWAS) of LOAD 13 have been linked to APP metabolism 14, 15 and Aβ-related pathways have not yet emerged in formal enrichment analyses. 16 Moreover, the genes involved in autosomal dominant forms of EOAD have not been detected in GWAS of LOAD.
To address these questions regarding the amyloid hypothesis, we and others have directly explored the genetics of Aβ through GWAS on quantitative measures of Aβ peptides, either in the cerebrospinal fluid (CSF) or in the brain, through Pittsburgh Compound B (PiB) PET scan or autopsy. [17] [18] [19] [20] [21] Combining the effect of AD genetic loci resulted in statistically significant effects on CSF Aβ42, suggesting that amyloid metabolism is also involved in LOAD. 21 Nevertheless, these studies are limited in their sample size due to low acceptability of lumbar puncture and brain donation and high cost of PiB PET, and therefore may lack statistical power necessary in genetic association research. Aβ peptides produced in the brain can be degraded locally or transported into the CSF and the blood stream where they can be easily detected. 22 Although the brain-derived Aβ peptides in the circulation cannot be distinguished from Aβ derived from blood platelets or pancreas, plasma Aβ levels are modestly but significantly correlated with amyloid burden in the CSF and in the brain. 23, 24 Our groups have also independently shown that plasma Aβ concentrations are prospectively associated with the future risk of developing AD, [25] [26] [27] [28] suggesting that there is indeed a link between mechanisms controlling Aβ concentrations in plasma and AD pathophysiological processes in the brain and that circulating Aβ peptides can be used as a marker for brain amyloid metabolism. Alternatively, it has also been postulated that the relation of plasma Aβ with subsequent AD is reflecting general physiological processes in the brain, platelets and kidney, thus giving information on Aβ peptides production/clearance in each of these tissues. 29 In this context, we set out to discover genetic determinants of circulating Aβ. We previously conducted a GWAS of plasma Aβ levels in 3,528 non-demented participants, but failed to find genome-wide significant associations. 29 The present study extends our previous work by performing a GWAS using a sample size (n=12,369) that is more than three times larger.
Methods

Study population
We included data from 12,369 European-descent participants from eight studies, the Framingham Heart Study (FHS; n=6,735), the Rotterdam study (n=1,958), the Three City Study (3C; n=1,954), the Atherosclerosis Risk in Communities Study (ARIC; n=830), the Washington Heights-Inwood Community Aging Project (WHICAP; n=193), the Epidemiological Prevention study Zoetermeer (EPOZ; n=397), the Alzheimer's Disease Neuroimaging Initiative (ADNI; n=173) and the Erasmus Rucphen Family Study (ERF; n=129). In each study, we excluded participants with prevalent dementia at the time of blood sampling used for plasma Aβ assessment (see Supplementary Methods 1 for a detailed description of each study).
Plasma Aβ assessment
Each study used different protocols for blood sampling, plasma extraction and storage and plasma Aβ assessment that have been detailed in previous publications. 25, 26, 28, [30] [31] [32] In the FHS, Rotterdam and 3C study, plasma Aβ levels were measured at different times because of cost considerations. Various assays were used to quantify plasma Aβ1-40 and Aβ1-42 levels (see Supplementary Methods 2 for a detailed description of the protocols used in each study and Supplementary Table 1 for baseline characteristics of the study populations).
Genotyping
Each study used different genotyping platforms as previously published.
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After applying pre-imputation variant and sample filters, genotypes were imputed using the 1000 Genomes phase 1 version 3 (all ethnicities) imputation panel and various imputation pipelines (see Supplementary Methods 3). APOEε genotyping was performed as part of protocols specific to each study (see Supplementary Methods 4).
Statistical analyses Plasma Aβ levels
Plasma Aβ levels were expressed as pg/mL. In each study and for each Aβ dosage, we excluded values that were over or below 4 standard deviations around the mean. To study the variations of plasma Aβ levels in a consistent way across studies, we performed a ranked-based inverse normal transformation of plasma Aβ levels in each study. If they were significantly associated with plasma Aβ levels, this transformation was performed after adjusting for batch effect and other technical artifacts.
Genome-wide association studies
Each study performed genome-wide association studies of plasma Aβ1-40 and Aβ1-42 levels and Aβ1-42/Aβ1-40 ratio using 1000 Genomes imputed data. According to the imputation pipelines used, genetic information was available either as allele dosages or genotype probabilities. In each study, we excluded results from variants that had low imputation quality (r2 or info score < 0.3), variants with low frequency (minor allele frequency < 0.005 or minor allele count < 7) and variants that were available in small number of participant (n < 30). Association of genetic variations with plasma Aβ levels were assessed in linear regression models adjusted for sex and age at blood collection. If significantly associated with plasma Aβ levels, principal components were added in the models to account for population structure.
Genome-wide meta-analysis
Before meta-analysis, we applied a series of filters and quality check that were previously published (see Supplementary Figures 1 and 2) . 33 We performed an inverse variance weighted genome-wide meta-analysis, accounting for genomic inflation factors using the METAL software. 34 Finally, we retained variants that had been meta-analyzed at least in the 3 largest available populations (FHS (n=6,735), Rotterdam Study (RS; n=1,958) and Three City Study (3C; n=1,954)). Statistical significance was defined as a p-value below 5×10-8. Signals with p-values between 1×10-5 and 5×10-8 were considered suggestive. Additional graphes and analyses were done using R v3.4.1 (Vienna, Austria).
Confirmation of the APOEε4 signal
To confirm the APOE signal we obtained in our genome-wide meta-analysis, we reran our analysis using genotyped APOEε4 and APOEε2 status, adjusting for age and sex.
Annotation
Variant information were retrieved using the Feb 2009 (grch37) assembly of the human genome and dbSNP v147 in the UCSC Table Browser web tool (https://genome.ucsc.edu/cgi-bin/hgTables accessed on 2017-07-25)and the CADD database version 1.3 (http://cadd.gs.washington.edu/download accessed on 2017-07-26). 35 We considered that variants that were less than 250kb apart from one another belonged to the same locus. We then used the Ensembl Variant Effect Predictor (VEP, http://grch37.ensembl.org/info/docs/tools/vep/index.html accessed on 2017-07-25) 36 to relate those variants to nearby genes of potential interest. We also searched if those variants were also eQTL for nearby genes using data from the Genotype-Tissue Expression (GTEx) project (https://gtexportal.org/home/) 37 using the Ensembl REST API (http://rest.ensembl.org/documentation/info/species_variant, data retrieved on 2017-07-31). We corrected for multiple testing by computing False Discovery Rate (FDR), using an FDR threshold of 0.05. Finally, we cross-checked our results with previously published GWAS of AD 13 amyloid-related brain pathology, 19 and CSF Aβ42 levels.
Genetic correlations
To gain further insight, we used the LD SCore software v1.0.0 38, 39 and previously published GWAS to compute genetic correlations between plasma Aβ levels and ratio and AD, 
Results
Genome-wide significant variants associated with plasma Aβ levels
After meta-analysis, we identified 21 variants reaching genome-wide significance across two loci (Supplementary Figures 3 to 8 ).
The first locus was located on chromosome 19, in the APOE gene, with significant associations with plasma Aβ1-42 levels and plasma Aβ1-42/Aβ1-40 ratio (Figures 1 and  2 ). For both associations, the most significant variant was rs429358, with p-values of 9.01 × 10-13 and 6.46 × 10-20 for Aβ1-42 levels and Aβ1-42/Aβ1-40 ratio, respectively (Table 1 ). The minor allele of this variant, which denotes the APOEε4, was associated with lower plasma Aβ1-42 levels (effect size=-0.167 standard deviations (SD); 95% confidence interval (CI)=[-0.212 ; -0.121]) and lower plasma Aβ1-42/Aβ1-40 ratio (effect size=-0.212 SD; 95% CI=[-0.257 ; -0.121]; Table1 and Supplementary Figure 9 ). We confirmed these associations using the directly genotyped APOEε4 status (Supplementary Figure 10) . We did not find significant associations between genotyped APOEε2 and circulating Aβ peptides levels, despite the protective effect of this variant on the risk of AD (Supplementary Figure 10) .
The second genome-wide significant locus was located on chromosome 11, near the BACE1 gene that encodes the β-secretase and is involved in the initial, Aβ-producing step of APP processing (Figure 3 ). For the most significant variant, rs650585 (CADD score=6), the minor allele was associated with lower plasma Aβ1-40 levels (effect size=-0.073 SD; 95%CI=[-0.099 ; -0.047]; p-value=2.56 × 10-8; Table1 and Supplementary Figure 9 ). This variant was in moderate LD (R2=0.58) with a BACE1 synonymous variant, rs638405 (CADD score=11), which was also associated with plasma Aβ1-40 levels (effect size=-0.071 SD, p-value=1.21 × 10-7). Both variants were associated with BACE1 expression in testis (FDR=4.52 × 10-11 and FDR=2.62 × 10-38, respectively). rs638405 was also associated with CEP164 expression in the cerebellum (FDR=2.05 × 10-6; Supplementary Table 2 ). Of note, this locus also contained a missense variant in the CEP164 gene that was associated with plasma Aβ1-40 levels with suggestive levels of significance (rs573455, effect size=-0.057 SD; p-value=9.16 × 10-6).
GWAS suggestive hits
Besides genome-wide significant signals at the APOE and BACE1 loci, signals reaching suggestive levels of association (p<1 × 10-5) for at least one of the three plasma Aβ measures were identified for 240 variants across 73 loci.
Interestingly, we found suggestive levels of association spread across three peaks within and nearby APP, one of the core genes of amyloid metabolism (Figure 4) . Two independent variants located within APP were suggestively associated with plasma Aβ1-40 levels: rs150707803 (effect size=-0.184 SD; p-value=2.10 × 10-6) and rs436011 (effect size=0.061 SD; p-value=3.92 × 10-6) ( Figure 4A and Table 2 ). SNPs within this second locus, including rs436011, were associated with APP expression in the "Esophagus -Muscularis" (FDR=6.29 × 10-7 for rs436011; Supplementary Table 2 ). The top variant of the third locus, rs199744263, was located upstream of APP ( Figure 4B ). This variant was associated with lower Aβ1-42/Aβ1-40 ratio (effect size=-0.075 SD; pvalue=2.43 × 10-6; Table 2 ). SNPs from this locus were associated with brain expression of AP000230.1, a lincRNA located directly upstream of APP (e.g. for rs199744263, FDR=8.33 × 10-5 for cerebellar hemisphere expression; Supplementary Table 2 ).
In addition to BACE1 and APP, we explored genetic associations around other genes closely involved with Aβ production, namely PSEN1 and PSEN2 which are part of the γ-secretase complex and ADAM10, which encode for the α-secretase, and is involved in a competing, non-Aβ producing, processing of APP. There was a suggestive association with plasma Aβ1-40 at the PSEN2 locus (Table 3 , Supplementary Figure 11 ). In this locus, the top variant, rs2246221 (effect size= 0.057 SD; p-value=8.09 × 10-6) was also associated with PSEN2 expression in spleen (FDR=2.35 × 10-6), thyroid (FDR=1.77 × 10-5), lung (FDR=8.08 × 10-5), skin (FDR=1.76 × 10-2) and transformed fibroblasts (FDR=6.25 × 10-23; Supplementary Table 2 ). Finally, we found a suggestive association with plasma Aβ1-40 within RGS6 which is located approximately 600kb upstream of PSEN1 but did not find any evidence of eQTL linking the two loci (Table 3 , Supplementary Figure 12 ).
To minimize risk of false positive signal among the remaining suggestive loci, we prioritized 12 loci containing exonic variants or variants with a CADD score higher than 10 (Supplementary Table 3 ). Among these variants, rs11123523 (CADD=12.2), located near the TMEM37 gene, showed the lowest p-value. This variant was associated with plasma Aβ1-40 levels (effect size=-0.074; p-value=2.80 × 10-7) and was associated with expression of a nearby gene, SCTR, in thyroid (FDR=3.34 × 10-10), testis (FDR=9.45 × 10-3) and tibial nerve (FDR=1.63 × 10-2). The only exonic variant was rs704, a missense variant of the VTN gene associated with plasma Aβ1-40 levels (effect size=-0.060; p-value=5.81 × 10-6).
Genetic overlap with other Aβ-related traits and diseases
In order to put those genome-wide significant variants in the context of amyloid-related pathophysiology of AD, we compared them with results obtained from CSF Aβ42, AD brain pathology and AD risk in GWAS ( Table 1 ). The APOE 4 allele was also associated ɛ with lower CSF Aβ42 levels, higher brain levels of neuritic plaques, diffuse plaques and neurofibrillary tangles and higher risk of AD. For the BACE1 locus, we did not find genome-wide significant or suggestive associations of rs650585 with any of the aforementioned traits. Among suggestive variants, no genome-wide significant or suggestive association was found for any of the other amyloid-related traits or for AD risk.
To improve statistical power, we performed a genetic correlation analysis of GWAS results of multiple traits using LD regression. On a genome-wide scale ( Figure 5 ), we observed a nominally significant negative genetic correlation between variants modulating plasma Aβ1-40 levels and hippocampal volume (rg=-0.64, p=0.03), and a
Discussion
Previous genome-wide association studies of plasma Aβ40 and Aβ42 levels have failed to uncover genome-wide significant findings. In this study, we identified two genome-wide significant loci associated with plasma Aβ levels in up to 12,369 non-demented subjects of European ancestry. The top variant in the first locus, rs429358, a well-known non-synonymous variant that encodes for the APOE4 isoform, was associated with lower circulating Aβ42 levels and Aβ42/40 ratio. In the second, located near BACE1, rs650585 was associated with lower plasma Aβ40 levels.
The BACE1 region encompasses several genes (PCSK7, RNF214, BACE1, CEP164) and a BACE1 anti-sense long non-coding RNA (BACE1-AS). Since the β-secretase activity of BACE1 is necessary for Aβ peptide production, it is likely that BACE1 or a local regulation of BACE1 expression are responsible for this signal. We also found suggestive associations with plasma Aβ40 levels near APP and PSEN2, two major actors of the Aβ metabolism. APP is obviously a central element of its own metabolism and PSEN2 is a key component of the γ-secretase which processes the APP C99 fragment into Aβ peptides. 1 We speculate that the effect of the variants on the expression/biological activation of these key elements of β-amyloid processing is strong enough to allow their detection at the plasma level, despite the influence of many other simultaneous biological processes, e.g. secretion, interaction with other proteins, degradation and/or clearance. Moreover, the top variants at the PSEN2 and BACE1 locus were also nominally associated with Aβ42 levels in the same direction as Aβ40 levels, which is in agreement with knowledge that PSEN2 and BACE1 activities indifferently produce Aβ40 and Aβ42 peptides.
Conversely, the APOEε4 allele had the strongest association with Aβ42 levels but was not even nominally associated with Aβ40. In line with our previous comment, this suggests that the APOE4 isoform is not involved in the early process of Aβ peptide production but in more downstream events, such as Aβ aggregation or clearance. These results might also illustrate the greater ability to aggregate of Aβ42 peptides compared to Aβ40, and the influence of APOE isoforms in the regulation of this process. 8 Interestingly, associations of APOEε2 with plasma Aβ levels were not significant and effect sizes were very small. Contrary to APOEε4, the effect of APOEε2 on amyloid markers has been much less studied and seems to be focused on specific brain regions, which could explain why we could not detect any association. 48 This could also suggest that other, Aβ-independent, mechanisms are involved in the lower risk of AD observed in APOEε2 carriers. 49 Given the presence of suggestive associations around known APP/Aβ genes, it is likely that novel and relevant signals exist within this range of statistical significance, awaiting definite validation. In order to minimize the risk of false positive result, we used exonic location and CADD score as additional filters to screen for SNPs of interest. Among those, we observed an association between a missense mutation of the VTN gene and lower plasma Aβ40 levels. VTN encodes for vitronectin, a glycoprotein present in abundance in the plasma and the extracellular matrix and involved in early regulation of thrombogenesis and tissue repair.
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Vitronectin has been associated with amyloid deposits, 51 including Aβ, both at the level of amyloid plaques in the brain 52 and near the retinal pigment epithelium in the aging eye. 53 Modest correlation between plasma vitronectin and brain amyloid burden measured by PiB PET has been reported. 54 Vitronectin is involved in microglial activation, 55 which is relevant to AD pathophysiology. 56 Vitronectin might also be involved in small vessel disease. In a mouse model of CADASIL, an autosomal dominant disease responsible for stroke and cognitive impairment, reduction of vitronectin expression resulted in less white matter lesions. 57 Vitronectin could therefore represent a promising candidate to study mechanisms linking Aβ peptides with Aβ-related pathologies, such as AD, cerebral amyloid angiopathy and small vessel disease. Other potential genes of interest close to suggestive signals warrant further investigation. For example, SCTR, encoding for secretin receptor, is involved in a wide range of physiological functions, beyond the scope of this study. Interestingly though, a study reported that mice deficient for that gene display impaired hippocampal synaptic plasticity. 58 Although research on variants associated with levels of circulating amyloid peptides is of general interest for Aβ physiology, we are interpreting the findings primarily from the perspective of brain disorders, especially AD. When cross-checking our results with other published GWAS of CSF and brain Aβ, and AD, we observed consistent results only with the APOEε4 variant. As expected, this variant was associated with low plasma and CSF Aβ42, high brain Aβ and AD risk, consistent with a differential effect of APOE isoforms on Aβ aggregation and clearance from the brain. When interpreting the absence of significant association between variants in the other loci and those same traits, one should keep in mind that their effect on plasma Aβ levels was generally smaller compared to that of APOEε4 so we might be underpowered to detect a significant association. It is also of interest that the LD-score regression analysis suggested a positive correlation of variants modulating plasma Aβ1-42 levels and white matter lesions and a negative correlation between plasma Aβ40 and hippocampal volume. Nevertheless, these genetic correlations were only nominally significant and await replication.
Plasma Aβ is usually considered as a poor biomarker of AD in the literature. A previous meta-analysis reported that plasma Aβ levels were not useful to make a clinical diagnosis of AD. 59 Nevertheless many of the cohorts participating in the present study have previously reported that low plasma Aβ42 and Aβ42/40 ratio levels were associated with development of AD after several years of follow-up.
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These results are consistent with an early, preclinical, involvement of Aβ in AD pathophysiology and are strengthened by our present observation that APOEε4, is both associated with low plasma Aβ42 and Aβ42/40 ratio and high AD risk. Some of those studies have also reported that this association remained significant after adjusting for APOEε4, 28 and we might hypothesize that variations of plasma Aβ levels are not only a side-effect of APOEε4, but are also involved in AD pathophysiology. As such, plasma Aβ levels would not be only useful as a biomarker of an active amyloid process in the brain but could also be considered as a therapeutic target. In favor of this hypothesis are reports that hemodialysis or peritoneal dialysis are able to lower Aβ in the brain.
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The association we observed between variants near BACE1 and plasma Aβ40 is also of interest in the light of the ongoing trials testing BACE inhibitors, even though the lack of association of these variants with AD risk should be further investigated. 62 Our study has several strengths. First, it is, to date, the largest study of circulating amyloid peptides. This enabled us to identify known actors of Aβ metabolism and, thus, to be optimistic about the relevance of some of our suggestive signals. Second, this study was conducted in non-demented participants and therefore is relevant for the study of early amyloid pathophysiological processes. Third, we carefully normalized the plasma Aβ data before running GWAS, thus taking into account some of the heterogeneity that has been described when using plasma Aβ levels.
Our study has also limitations worth mentioning. As stated before, the state of current knowledge makes it hard for us to extrapolate the role of these actors from the plasma compartments to the brain and further research in this area is needed. Second, the assays used in this study non-selectively measured Aβ concentrations and could not distinguish monomers from oligomers of Aβ, whether free or protein-bound. Therefore, our interpretation of the present results might differ from other studies in which assays used selectively measured monomers or oligomers of Aβ. 63 Future studies should carefully choose assays that allow measurements of each form of Aβ as this will facilitate interpretation with regard to the balance between Aβ production, aggregation and clearance. Finally we tried to prioritize signals of interest using strict criteria, thus omitting to mention other interesting signals that might be real. Therefore we hope that the unfiltered results from this study, will be helpful as a resource to the scientific community to further decipher the physiology of Aβ peptides and its links to pathophysiology of AD and other Aβ-related diseases.
In summary, our results indicate that genetic determinants of plasma Aβ40 and Aβ42 levels are close to genes known to be central actors in APP metabolism in AD. Further increasing the statistical power of plasma Aβ analyses may potentially lead us to the identification of currently unknown players in Aβ metabolism, novel hypotheses and hopefully, new preventive or therapeutic targets against Alzheimer's disease. Figure 1 . Association of frequent genetic variants with plasma Aβ1-42 in the APOE locus Table 1 . Associations of top variants from genome-wide significant loci with plasma Aβ levels and amyloid-related traits Table 2 . Associations of top variants from the APP locus with plasma Aβ levels and amyloid-related traits Table 3 . Associations of top SNPs from the PSEN1 and PSEN2 locus with plasma Aβ levels and amyloid-related traits Recombination rate (cM/Mb)
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